· Published by Health Canada · Official notice
This is duplicated text of a letter from Hoffman-La Roche Limited.
Contact the company for a copy of any references, attachments or enclosures.
Notice about Health Canada advisories
November 2, 2010
Subject: Updated Safety Information for INVIRASE® (saquinavir mesylate): Specific Guidance on Monitoring Heart Activity Using Electrocardiography
Hoffmann-La Roche Limited, in consultation with Health Canada, would like to inform patients of safety updates to the prescribing information for INVIRASE (saquinavir mesylate).
INVIRASE is authorized for the treatment of HIV-1 infected adult patients. INVIRASE should only be given in combination with ritonavir and other antiretroviral products.
The Canadian Product Monograph, including Consumer Information, for INVIRASE has been revised to further emphasize the following safety concerns:
To inform health care professionals regarding the need to:
The current Canadian prescribing information for INVIRASE (Product Monograph) can be accessed on the Roche Canada Web site or by performing a search in Health Canada's Drug Product Database.
Please speak with your doctor or pharmacist if you have any related concerns or if you experience any other unexpected effects while taking INVIRASE.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-marketing adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of serious or unexpected adverse reactions in patients receiving INVIRASE should be reported to Hoffmann-La Roche Limited or Health Canada at the following addresses:
Hoffmann-La Roche Limited
Drug Safety Department
2455 Meadowpine Boulevard
Mississauga, Ontario, L5N 6L7
or call toll free at: 1-888-762-4388
or fax at: 905-542-5864
or email to: mississauga.drug_safety@roche.com
You can report any suspected adverse reactions associated with the use of health products to the Canada Vigilance Program by one of the following three ways:
The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffectTM Canada Web site in the Adverse Reaction Reporting section.
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate (MHPD)
E-mail: mhpd_dpsc@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
Should you have any questions or require additional information regarding the use of INVIRASE, please contact the Drug Information Department at Hoffmann-La Roche Limited at 1-888-762-4388 from 8:30 a.m. to 4:30 p.m. Monday to Friday Eastern Standard Time.
Sincerely,
original signed by
Lorenzo Biondi,
Vice President, Medical and Regulatory Affairs
Hoffmann-La Roche Limited